ArticleBMC infectious diseases2025
Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and/or reactivation antigen RpfE.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multifaceted DosR proteins of Mycobacterium tuberculosis: emerging roles for tuberculosis control.Archives of microbiology · 2026Review
- mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges.Archives of microbiology · 2026Review
- Screening and in silico evaluation of candidate late-stage antigens for incorporation into multi-stage and post-exposure vaccines against tuberculosis.NPJ vaccines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycobacterium bovis bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB), but it fails to prevent the establishment and reactivation of latent TB. Overexpression of latency and reactivation antigens by BCG may enhance its efficacy against latent infection and subsequent reactivation. This study aimed to construct recombinant BCG strains (rBCGs) overexpressing the latency antigen Rv1733c and/or resuscitation promoting factor E (RpfE).
methodsEpisomal (pJH222) or integrative (pJH223) plasmids-either empty or encoding rv1733c or rpfE-were transformed into a lysine auxotroph strain of BCG for lysine complementation. The resulting rBCGs were genetically and phenotypically characterized. Female BALB/c mice underwent a six-month vaccination regimen consisting of a homologous prime-boost immunisation with the rBCGs, followed by a heterologous boost with Rv1733c and/or RpfE recombinant proteins. Splenocytes from immunised mice were stimulated ex vivo with purified protein derivative (PPD) or the corresponding recombinant protein(s) to measure secreted cytokines.
resultsThe rBCGs carrying episomal recombinant plasmids encoding rv1733c or rpfE elicited higher levels of antigen-specific interferon-gamma (IFN-γ) compared to empty-vector controls. rBCG strains with integrative constructs encoding either antigen induced higher levels of tumour necrosis factor-alpha relative to the sham, wild-type BCG, and empty-vector groups. All rBCGs expressing either or both antigens generated more favourable IFN-γ to interleukin (IL)-10 ratios upon stimulation with their respective antigen(s) than with PPD. While two rBCGs elicited detectable IL-4 responses, the rBCGs expressing both antigens did not induce IL-4.
conclusionsThis study demonstrates promising immunogenicity of the latency antigen Rv1733c and the resuscitation antigen RpfE, highlighting their potential to enhance BCG efficacy through a tailored prime-boost vaccination strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.